

HÃ¥kon Reikvam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/210249/publications.pdf>

Version: 2024-02-01

117
papers

2,231
citations

186209

28
h-index

289141

40
g-index

119
all docs

119
docs citations

119
times ranked

2819
citing authors

#	ARTICLE	IF	CITATIONS
1	The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2907.	1.8	158
2	Thrombelastography. <i>Transfusion and Apheresis Science</i> , 2009, 40, 119-123.	0.5	130
3	Acute Myeloid Leukemia with the t(8;21) Translocation: Clinical Consequences and Biological Implications. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-23.	3.0	69
4	Therapeutic Targeting the Cell Division Cycle 25 (CDC25) Phosphatases in Human Acute Myeloid Leukemia – The Possibility to Target Several Kinases through Inhibition of the Various CDC25 Isoforms. <i>Molecules</i> , 2014, 19, 18414-18447.	1.7	67
5	The cytokine-mediated crosstalk between primary human acute myeloid cells and mesenchymal stem cells alters the local cytokine network and the global gene expression profile of the mesenchymal cells. <i>Stem Cell Research</i> , 2015, 15, 530-541.	0.3	51
6	Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation. <i>European Journal of Haematology</i> , 2010, 84, 239-251.	1.1	50
7	Hyperferritinemia – A Clinical Overview. <i>Journal of Clinical Medicine</i> , 2021, 10, 2008.	1.0	48
8	Nuclear Factor- κ B Signaling: A Contributor in Leukemogenesis and a Target for Pharmacological Intervention in Human Acute Myelogenous Leukemia. <i>Critical Reviews in Oncogenesis</i> , 2009, 15, 1-41.	0.2	47
9	Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells. <i>Signal Transduction and Targeted Therapy</i> , 2019, 4, 20.	7.1	46
10	The Chemokine Network in Acute Myelogenous Leukemia: Molecular Mechanisms Involved in Leukemogenesis and Therapeutic Implications. <i>Current Topics in Microbiology and Immunology</i> , 2010, 341, 149-172.	0.7	45
11	The angioregulatory cytokine network in human acute myeloid leukemia – from leukemogenesis via remission induction to stem cell transplantation. <i>European Cytokine Network</i> , 2012, 23, 140-153.	1.1	44
12	Pharmacologic targeting of the PI3K/mTOR pathway controls release of angioregulators from primary human acute myeloid leukemia cells and their neighboring stromal cells. <i>Oncotarget</i> , 2013, 4, 830-843.	0.8	43
13	Cytokines, Adhesion Molecules, and Matrix Metalloproteases as Predisposing, Diagnostic, and Prognostic Factors in Venous Thrombosis. <i>Frontiers in Medicine</i> , 2018, 5, 147.	1.2	42
14	FEBRILE NEUTROPENIA IN ACUTE LEUKEMIA. EPIDEMIOLOGY, ETIOLOGY, PATHOPHYSIOLOGY AND TREATMENT. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020009.	0.5	41
15	Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status – consequences and potentials for pharmacological intervention. <i>British Journal of Haematology</i> , 2012, 156, 468-480.	1.2	39
16	The Possible Importance of β 3 Integrins for Leukemogenesis and Chemoresistance in Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2018, 19, 251.	1.8	38
17	Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 169-183.	1.9	36
18	Altered plasma levels of cytokines, soluble adhesion molecules and matrix metalloproteases in venous thrombosis. <i>Thrombosis Research</i> , 2015, 136, 30-39.	0.8	36

#	ARTICLE	IF	CITATIONS
19	Targeted therapy in acute myeloid leukaemia: current status and future directions. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 433-455.	1.9	34
20	Antileukaemic effect of PI3K/mTOR inhibitors in acute myeloid leukaemia—gene expression profiles reveal CDC25B expression as determinate of pharmacological effect. <i>British Journal of Haematology</i> , 2014, 164, 200-211.	1.2	34
21	Extracorporeal photopheresis (photochemotherapy) in the treatment of acute and chronic graft versus host disease: immunological mechanisms and the results from clinical studies. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 757-777.	2.0	34
22	The pretransplant systemic metabolic profile reflects a risk of acute graft versus host disease after allogeneic stem cell transplantation. <i>Metabolomics</i> , 2016, 12, 12.	1.4	34
23	The Pretransplantation Serum Cytokine Profile in Allogeneic Stem Cell Recipients Differs from Healthy Individuals, and Various Profiles are Associated with Different Risks of Posttransplantation Complications. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 190-199.	2.0	33
24	Therapeutic targeting of leukemic stem cells in acute myeloid leukemia—the biological background for possible strategies. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 1053-1065.	2.5	32
25	Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: Serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment. <i>American Journal of Hematology</i> , 2012, 87, 368-376.	2.0	31
26	Splenic tyrosine kinase (SYK) inhibitors and their possible use in acute myeloid leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 377-387.	1.9	30
27	The Possible Diagnostic and Prognostic Use of Systemic Chemokine Profiles in Clinical Medicine—The Experience in Acute Myeloid Leukemia from Disease Development and Diagnosis via Conventional Chemotherapy to Allogeneic Stem Cell Transplantation. <i>Toxins</i> , 2013, 5, 336-362.	1.5	29
28	The Mirasol Pathogen Reduction Technology system and quality of platelets stored in platelet additive solution. <i>Blood Transfusion</i> , 2010, 8, 186-92.	0.3	29
29	Thrombosis and thrombocytopenia after HPV vaccination. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 700-704.	1.9	29
30	Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 551-563.	1.9	28
31	Pretransplant Levels of CRP and Interleukin-6 Family Cytokines; Effects on Outcome after Allogeneic Stem Cell Transplantation. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1823.	1.8	27
32	Trisomy 8 in acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2019, 12, 947-958.	1.0	27
33	A Subset of Patients with Acute Myeloid Leukemia Has Leukemia Cells Characterized by Chemokine Responsiveness and Altered Expression of Transcriptional as well as Angiogenic Regulators. <i>Frontiers in Immunology</i> , 2016, 7, 205.	2.2	26
34	Bronchiolitis obliterans syndrome in adults after allogeneic stem cell transplantation—pathophysiology, diagnostics and treatment. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 553-569.	1.3	26
35	High Constitutive Cytokine Release by Primary Human Acute Myeloid Leukemia Cells Is Associated with a Specific Intercellular Communication Phenotype. <i>Journal of Clinical Medicine</i> , 2019, 8, 970.	1.0	26
36	Bacterial contamination of blood components: Norwegian strategies in identifying donors with higher risk of inducing septic transfusion reactions in recipients. <i>Transfusion and Apheresis Science</i> , 2014, 51, 97-102.	0.5	25

#	ARTICLE	IF	CITATIONS
37	Targeting Cellular Metabolism in Acute Myeloid Leukemia and the Role of Patient Heterogeneity. <i>Cells</i> , 2020, 9, 1155.	1.8	25
38	Identification of a subset of patients with acute myeloid leukemia characterized by long-term <i>in vitro</i> proliferation and altered cell cycle regulation of the leukemic cells. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 1237-1251.	1.5	24
39	Effects of cytarabine on activation of human T cells – cytarabine has concentration-dependent effects that are modulated both by valproic acid and all-trans retinoic acid. <i>BMC Pharmacology & Toxicology</i> , 2015, 16, 12.	1.0	24
40	Clonal Heterogeneity Reflected by PI3K-AKT-mTOR Signaling in Human Acute Myeloid Leukemia Cells and Its Association with Adverse Prognosis. <i>Cancers</i> , 2018, 10, 332.	1.7	24
41	Targeting of polo-like kinases and their cross talk with Aurora kinases – possible therapeutic strategies in human acute myeloid leukemia?. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 587-603.	1.9	23
42	Patients with acute myeloid leukemia can be subclassified based on the constitutive cytokine release of the leukemic cells; the possible clinical relevance and the importance of cellular iron metabolism. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 357-369.	1.5	22
43	Cytokine Release Syndrome in the Immunotherapy of Hematological Malignancies: The Biology behind and Possible Clinical Consequences. <i>Journal of Clinical Medicine</i> , 2021, 10, 5190.	1.0	21
44	Resistance to the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human Acute Myeloid Leukemia Cells Is Associated with Altered Cell Metabolism. <i>International Journal of Molecular Sciences</i> , 2018, 19, 382.	1.8	20
45	Systemic levels of the endothelium-derived soluble adhesion molecules endocan and E-selectin in patients with suspected deep vein thrombosis. <i>SpringerPlus</i> , 2014, 3, 571.	1.2	19
46	The importance of sample collection when using single cytokine levels and systemic cytokine profiles as biomarkers – a comparative study of serum versus plasma samples. <i>Journal of Immunological Methods</i> , 2015, 418, 19-28.	0.6	18
47	Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia – identification of responders by gene expression profiling of pretreatment leukemic cells. <i>BMC Cancer</i> , 2017, 17, 630.	1.1	18
48	A prospective observational study of the effect of platelet transfusions on levels of platelet-derived cytokines, chemokines and interleukins in acute leukaemia patients with severe chemotherapy-induced cytopenia. <i>European Cytokine Network</i> , 2011, 22, 52-62.	1.1	17
49	Preconditioning Serum Levels of Endothelial Cell-Derived Molecules and the Risk of Posttransplant Complications in Patients Treated with Allogeneic Stem Cell Transplantation. <i>Journal of Transplantation</i> , 2014, 2014, 1-9.	0.3	15
50	Metabolic Serum Profiles for Patients Receiving Allogeneic Stem Cell Transplantation: The Pretransplant Profile Differs for Patients with and without Posttransplant Capillary Leak Syndrome. <i>Disease Markers</i> , 2015, 2015, 1-13.	0.6	15
51	Patients with Treatment-Requiring Chronic Graft versus Host Disease after Allogeneic Stem Cell Transplantation Have Altered Metabolic Profiles due to the Disease and Immunosuppressive Therapy: Potential Implication for Biomarkers. <i>Frontiers in Immunology</i> , 2017, 8, 1979.	2.2	15
52	Soluble mediators released by acute myeloid leukemia cells increase capillary-like networks. <i>European Journal of Haematology</i> , 2012, 89, 478-490.	1.1	14
53	Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 639-653.	1.5	14
54	The effects of selective serotonin reuptake inhibitors on platelet function in whole blood and platelet concentrates. <i>Platelets</i> , 2012, 23, 299-308.	1.1	13

#	ARTICLE	IF	CITATIONS
55	Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation. <i>Oncotarget</i> , 2015, 6, 2794-2811.	0.8	13
56	Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) – gene transcription, cell cycle regulation, metabolism and intercellular communication. <i>Expert Review of Hematology</i> , 2015, 8, 299-313.	1.0	13
57	Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 411-420.	1.9	13
58	Platelet Microparticles Protect Acute Myelogenous Leukemia Cells against Daunorubicin-Induced Apoptosis. <i>Cancers</i> , 2021, 13, 1870.	1.7	13
59	Toll-like Receptor 4, Osteoblasts and Leukemogenesis; the Lesson from Acute Myeloid Leukemia. <i>Molecules</i> , 2022, 27, 735.	1.7	13
60	CDC25 Inhibition in Acute Myeloid Leukemia – A Study of Patient Heterogeneity and the Effects of Different Inhibitors. <i>Molecules</i> , 2017, 22, 446.	1.7	12
61	Altered Immune Activation and IL-23 Signaling in Response to <i>Candida albicans</i> in Autoimmune Polyendocrine Syndrome Type 1. <i>Frontiers in Immunology</i> , 2017, 8, 1074.	2.2	12
62	Inhibition of NF- κ B Signaling Alters Acute Myelogenous Leukemia Cell Transcriptomics. <i>Cells</i> , 2020, 9, 1677.	1.8	12
63	Microcirculation and red cell transfusion in patients with sepsis. <i>Transfusion and Apheresis Science</i> , 2017, 56, 900-905.	0.5	11
64	Effects of the Autophagy-Inhibiting Agent Chloroquine on Acute Myeloid Leukemia Cells; Characterization of Patient Heterogeneity. <i>Journal of Personalized Medicine</i> , 2021, 11, 779.	1.1	11
65	Targeted Anti-leukemic Therapy as Disease-stabilizing Treatment for Acute Myeloid Leukemia Relapse after Allogeneic Stem Cell Transplantation: Will it be Possible to Combine these Strategies with Retransplantation or Donor Lymphocyte Infusions?. <i>Current Cancer Drug Targets</i> , 2013, 13, 30-47.	0.8	10
66	Hemophagocytic lymphohistiocytosis and miliary tuberculosis in a previously healthy individual: a case report. <i>Journal of Medical Case Reports</i> , 2020, 14, 217.	0.4	10
67	Comparison of in vitro responses to fresh whole blood and reconstituted whole blood after collagen stimulation. <i>Blood Transfusion</i> , 2014, 12, 50-5.	0.3	10
68	Hematopoiesis, Inflammation and Aging – The Biological Background and Clinical Impact of Anemia and Increased C-Reactive Protein Levels on Elderly Individuals. <i>Journal of Clinical Medicine</i> , 2022, 11, 706.	1.0	10
69	Predicting effects of kinase inhibitor in therapy for myeloid malignancies – the challenges in capturing disease heterogeneity. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1365-1370.	1.9	9
70	Emerging therapeutic targets in human acute myeloid leukemia (part 2) – bromodomain inhibition should be considered as a possible strategy for various patient subsets. <i>Expert Review of Hematology</i> , 2015, 8, 315-327.	1.0	9
71	Concomitant Hemophagocytic Lymphohistiocytosis and Cytomegalovirus Disease: A Case Based Systemic Review. <i>Frontiers in Medicine</i> , 2022, 9, 819465.	1.2	9
72	Immunoglobulin-Storing Histiocytosis: A Case Based Systemic Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 1834.	1.0	8

#	ARTICLE	IF	CITATIONS
73	Cytokine profiling and post-transfusion haemoglobin increment in patients with haematological diseases. <i>Vox Sanguinis</i> , 2018, 113, 657-668.	0.7	7
74	Nutrition in Allogeneic Stem Cell Transplantation - Clinical Guidelines and Immunobiological Aspects. <i>Current Pharmaceutical Biotechnology</i> , 2015, 17, 92-104.	0.9	7
75	Untangling the intracellular signalling network in cancer – A strategy for data integration in acute myeloid leukaemia. <i>Journal of Proteomics</i> , 2011, 74, 269-281.	1.2	6
76	Questionnaire-Related Deferrals in Regular Blood Donors in Norway. <i>Journal of Blood Transfusion</i> , 2012, 2012, 1-4.	3.3	6
77	Heat shock protein 70 – the next chaperone to target in the treatment of human acute myelogenous leukemia?. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 929-944.	1.5	6
78	Myeloid Sarcoma after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Successful Consolidation Treatment Approaches in Two Patients. <i>Case Reports in Oncological Medicine</i> , 2018, 2018, 1-5.	0.2	6
79	Proteomic Studies of Primary Acute Myeloid Leukemia Cells Derived from Patients Before and during Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid and Valproic Acid. <i>Cancers</i> , 2021, 13, 2143.	1.7	6
80	Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: Will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions?. <i>Current Cancer Drug Targets</i> , 2013, 13, 30-47.	0.8	6
81	MicroRNA serum profiles and chronic graft-versus-host disease. <i>Blood Advances</i> , 2022, 6, 5295-5306.	2.5	6
82	Non-curative surgery for aortoenteric fistula. <i>Journal of Surgical Case Reports</i> , 2017, 2017, rjx153.	0.2	5
83	The healthy donor profile of immunoregulatory soluble mediators is altered by stem cell mobilization and apheresis. <i>Cytotherapy</i> , 2018, 20, 740-754.	0.3	5
84	A patient with maculopapular rash and lichenoid skin damage caused by ponatinib. <i>Journal of International Medical Research</i> , 2020, 48, 030006052090366.	0.4	5
85	HFE Genotype, Ferritin Levels and Transferrin Saturation in Patients with Suspected Hereditary Hemochromatosis. <i>Genes</i> , 2021, 12, 1162.	1.0	5
86	An Abrupt Transition to Digital Teaching – Norwegian Medical Students and Their Experiences of Learning Output during the Initial Phase of the COVID-19 Lockdown. <i>Healthcare (Switzerland)</i> , 2022, 10, 170.	1.0	5
87	p53 Protein Isoform Profiles in AML: Correlation with Distinct Differentiation Stages and Response to Epigenetic Differentiation Therapy. <i>Cells</i> , 2021, 10, 833.	1.8	4
88	Therapeutic Use of Valproic Acid and All-Trans Retinoic Acid in Acute Myeloid Leukemia – Literature Review and Discussion of Possible Use in Relapse after Allogeneic Stem Cell Transplantation. <i>Pharmaceuticals</i> , 2021, 14, 423.	1.7	4
89	Patient Heterogeneity in Acute Myeloid Leukemia: Leukemic Cell Communication by Release of Soluble Mediators and Its Effects on Mesenchymal Stem Cells. <i>Diseases (Basel, Switzerland)</i> , 2021, 9, 74.	1.0	4
90	Pretransplant Systemic Lipidomic Profiles in Allogeneic Stem Cell Transplant Recipients. <i>Cancers</i> , 2022, 14, 2910.	1.7	4

#	ARTICLE	IF	CITATIONS
91	How should quality of life assessment be integrated in the evaluation of patients with acute myeloid leukemia?. Expert Review of Quality of Life in Cancer Care, 2016, 1, 373-387.	0.6	3
92	Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation. Case Reports in Hematology, 2018, 2018, 1-4.	0.3	3
93	Therapy for acute myelogenous leukemia revisited: moving away from a one-size-fits-all approach. Expert Review of Anticancer Therapy, 2021, 21, 5-8.	1.1	3
94	Proteomic Characterization of Spontaneous Stress-Induced In Vitro Apoptosis of Human Acute Myeloid Leukemia Cells; Focus on Patient Heterogeneity and Endoplasmic Reticulum Stress. Hemato, 2021, 2, 607-627.	0.2	3
95	Successful eradication of leptomeningeal plasma cell disease. Oxford Medical Case Reports, 2018, 2018, omy038.	0.2	2
96	Precision medicine for TP53-mutated acute myeloid leukemia. Expert Review of Precision Medicine and Drug Development, 2019, 4, 263-274.	0.4	2
97	Critical Upper Airway Obstruction as the First Symptom of Acute Myeloid Leukemia—An Anesthesiologic Reminder. Clinics and Practice, 2020, 10, 34-36.	0.6	2
98	Carbapenem-Resistant Enterobacteriaceae—Implications for Treating Acute Leukemias, a Subgroup of Hematological Malignancies. Antibiotics, 2021, 10, 322.	1.5	2
99	Intermediate-High Risk Pulmonary Embolism: The Use of Riociguat and Inferior Vena Cava Filter in a Situation of Recurrent Embolism following Insufficient Anticoagulation and Fibrinolytic Therapy. Case Reports in Anesthesiology, 2020, 2020, 1-5.	0.2	1
100	Pure Red Cell Aplasia with Del(20q) Sensitive for Immunosuppressive Treatment. Case Reports in Hematology, 2020, 2020, 1-6.	0.3	1
101	Future perspective: precision medicine to improve treatment results in the settings of allogenic stem cell transplantation for acute myelogenous leukemia. Expert Review of Precision Medicine and Drug Development, 2021, 6, 151-155.	0.4	1
102	Spontaneous Splenic Artery Rupture as the First Symptom of Systemic Amyloidosis. Case Reports in Critical Care, 2021, 2021, 1-6.	0.2	1
103	Future perspective: metabolism as a therapeutic target in acute myeloid leukemia — from Warburg to precision medicine. Current Medical Research and Opinion, 2021, 37, 2107-2111.	0.9	1
104	Survival Stratification In Acute Myeloid Leukemia By Single Cell Signal Profiling. Blood, 2013, 122, 2625-2625.	0.6	1
105	Single Cell Signaling Pharmacodynamics in a Phase 1b Trial of the Axl Inhibitor BGB324 in Acute Myeloid Leukemia. Blood, 2016, 128, 3995-3995.	0.6	1
106	Endocan in Acute Leukemia: Current Knowledge and Future Perspectives. Biomolecules, 2022, 12, 492.	1.8	1
107	Lymphoplasmacytic variant of multiple myeloma. EJHaem, 0, , .	0.4	1
108	Mondor's disease after extensive training with Nordic walking. Oxford Medical Case Reports, 2019, 2019, omz075.	0.2	0

#	ARTICLE	IF	CITATIONS
109	Surgical Treatment of Severe Bowel Obstruction as a Rare Complication Following Allogenic Hematopoietic Stem Cell Transplantation. <i>Transplantation</i> , 2020, 1, 102-110.	0.3	0
110	Kidney Failure and Abdominal Discomfort as Initial Signs of Extramedullary Acute Myelogenous Leukemia. <i>Clinics and Practice</i> , 2021, 11, 459-466.	0.6	0
111	Favorable outcome of a patient with an unclassifiable myelodysplastic syndrome/myeloproliferative neoplasm treated with allogeneic hematopoietic stem cell transplantation. <i>SAGE Open Medical Case Reports</i> , 2021, 9, 2050313X2098841.	0.2	0
112	Single Cell-Level Signaling Profiling of Acute Myeloid Leukemia Following Treatment with Axl Kinase Inhibitor BGB324. <i>Blood</i> , 2015, 126, 4931-4931.	0.6	0
113	Myeloproliferative neoplasier og JAK2-mutasjonar. <i>Tidsskrift for Den Norske Lægeforening</i> , 2016, 136, 1889-1894.	0.2	0
114	Severe Nephritis as Initial Sign of Waldenström's Macroglobulinemia. <i>Clinics and Practice</i> , 2019, 9, 127-132.	0.6	0
115	Basosquamous Basal Cell Carcinoma with Bone Marrow Metastasis. <i>Current Oncology</i> , 2022, 29, 2193-2198.	0.9	0
116	Proteomic approaches for untangling pharmacological targets in acute myelogenous leukemia. <i>Expert Review of Proteomics</i> , 2022, , .	1.3	0
117	Cytomegalovirus induced hemophagocytic lymphohistiocytosis: diagnostic and treatment challenges for the future. <i>Expert Review of Hematology</i> , 0, , .	1.0	0